Company profilePharmaceutical#558 of 1,318 in Pakistan✓ No DRAP alerts

Cunningham Pharmaceuticals (Pvt.) Ltd. DML: 000840

Pharmaceutical company · 22 brands · 62 molecules

Ranked #12 of 25 companies in Other Anti-Baterials

22 registered products 14 pharmaceutical brands 62 distinct molecules 0 DRAP alerts

Company overview

22
registered products
14
pharmaceutical brands
62
distinct molecules
1
therapeutic classes
0
DRAP alerts

Cunningham Pharmaceuticals (Pvt.) Ltd. DML: 000840 is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 22 product registrations across 62 distinct molecules. Its portfolio is concentrated in Other Anti-Baterials. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Top molecules by brand count

Azithromycin....................250Mg2 brands
Azithromycin2 brands
Ketamine1 brand
Ketamine ...... 50Mg1 brand
Levetiracetam ...... 500 Mg1 brand
Levetiracetam ...... 1 Gm1 brand
Levetiracetam ...... 250 Mg1 brand
Levetiracetam ...... 750 Mg1 brand
Potassium Iodide ...... 65 Mg1 brand

Therapeutic classes

Other Anti-Baterials · 1

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official40 products · Rs 36.3 – Rs 120,443.05
Median across source: Rs 312.75

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

HIGH - Q INTERNATIONAL27 shared molecules
Pharmasol (Pvt) Ltd.25 shared molecules
BIO LABS (PVT) LTD.24 shared molecules
NAVEGAL LABORATORIES22 shared molecules

Get the full profile for Cunningham

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.